Histiocytic sarcoma (HS) is an aggressive malignant neoplasm of dendritic cell origin that is common in certain breeds of dogs. High prevalence of fatal, disseminated HS has been described in Bernese Mountain Dogs (BMDs). Support for genetic predisposition to develop HS has been presented in several studies, but to date, causative genetic events have not been reported. In addition, no driver mutations have been identified in tumours. Recently, E76K
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gain-of-function mutation in SHP2 encoded by the PTPN11 gene has been described in human histiocytic malignancies. In our study, we identified the PTPN11 E76K in HS of BMDs. Amplification of exon 3 of the PTPN11 gene followed by Sanger sequencing was used to detect the mutation and estimate the prevalence in HS from 30 BMDs, 13 Golden Retrievers and 10 other dog breeds. The overall prevalence of PTPN11 E76K in HS of BMDs was 36.67% compared with 8.69% in other breeds. No mutation was identified in normal tissues from 10 BMDs with HS that carried the mutation and 12 control dogs with no neoplastic disease, including 6 BMDs.
Increased immunoreactivity for AKT, phosphorylated ERK1/2 and phosphorylated AKT in a small subset of BMDs with PTPN11 E76K suggests that a gain-of-function might be mediated by the ERK and AKT pathways. These data suggest PTPN11 E76K as an important driver mutation of HS in BMDs. This information may not only aid in unravelling the tumourigenic events associated with HS in BMDs, but also help in identifying more promising therapeutic strategies.
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| INTRODUCTION
Histiocytic sarcoma (HS) is the most aggressive entity in the spectrum of histiocytic diseases in dogs. 1 
HS was first recognized in Bernese
Mountain Dogs (BMDs), 2 as a neoplasm derived from cells with the phenotypic profile of interstitial dendritic cells. 3 While HS has been sporadically reported in retriever dogs and other dog breeds, BMDs are considered to be a predisposed breed for HS with a polygenic mode of inheritance. [4] [5] [6] The disseminated form of HS has a strong negative prognosis and occurs most frequently in BMDs. Moreover, the median age of diagnosis of HS is earlier in BMDs than in Golden
Retrievers or other dog breeds. 7 Therefore, it has been suggested that the potential breed-specific genetic background may be responsible for the tumourigenesis of HS in BMDs. [5] [6] [7] The genomic loci involved in HS in BMDs and Flat-Coated
Retrievers have been studied extensively, 8, 9 but not definitively.
Evaluation of genome-wide copy number aberrations (CNAs) revealed recurrent CNAs common to HS. CNAs in tumour suppressor gene loci (CDKN2A/B, RB1 and PTEN) were detected in HS in both breeds, suggesting that these genetic alterations are more likely associated with a high risk to develop HS than with specific breeds. 8 HSassociated loci in BMDs were investigated, and BMDs in North America and Europe shared the same HS-associated locus, which features a single haplotype spanning MTAP and part of CDKN2A and is present in 96% of affected BMDs. 9 While impaired expression of CDKN2A and CDKN2B genes with INK4A/ARF/INK4B dysregulation is considered a primary contributor to HS susceptibility in BMDs, neither a causative genetic event nor driver mutation of HS in BMD has yet been identified.
In humans, HS is a rare neoplasm that tends to have an aggressive course and responds poorly to treatment. 10 The most frequent mutations in human HS cases were those identified in the BRAF gene, suggesting its role as a driver mutation favouring malignant transformations via constitutive activation of the Ras/Raf pathway.
11
Recently mutations in other genes, including KRAS, PTEN, PIK3CA, ASXL1, KIT, TP53 and PTPN11, were detected in HS using nextgeneration sequencing. 
| Genomic DNA preparation
Genomic DNA was extracted from formalin-fixed paraffin-embedded tissue sections obtained from all tumour tissues. Haematoxylin-and eosin-(H&E) stained sections were examined microscopically, and areas of tumour and normal tissue were marked. Tumour areas in the paraffin-embedded block were macrodissected with a scalpel, and then deparaffinized with 1 mL CitriSolv Clearing Agent (Fisher Scientific, Pittsburgh, PA) and washed twice in 1 mL of 100% ethanol.
Genomic DNA was extracted using the RecoverAll Kit (Thermo Fisher Scientific, Inc., Carlsbad, CA) following the manufacturer's protocol.
The quantity of the extracted DNA was determined using a Qubit 2.0 fluorometer (Thermo Fisher Scientific, Inc., Carlsbad, CA).
| Polymerase chain reaction and direct Sanger sequencing to detect the PTPN11 E76K mutation
Sanger sequencing was used to identify the mutation. Primer pairs for the TPTN11 gene (Ensembl:ENSCAFG00000008894) flanking the E76K mutation site within exon 3 were designed using Primer3 soft- PCR products were visualized on The QIAxcel Capillary Electrophoresis System (Qiagen, Valencia, CA) to confirm the presence of single product. PCR products were purified using the QIAquick PCR Purification Kit (Qiagen, Valencia, CA) and further submitted for sequencing using capillary electrophoresis on an ABI PRISM 3130 Genetic Analyzer (Thermo Fisher Scientific, Inc., Foster City, CA). Sanger sequencing results were aligned to reference normal gene sequence. [17] [18] [19] [20] The D17 canine osteosarcoma cell line known to express these proteins was used as a positive control. 21, 22 To mirror tissue fixation, cell line pellets had been embedded in histogel followed by fixation in 10% neutral buffered formalin and paraffin embedding. Primary antibodies were replaced by homologous nonimmune sera for negative controls.
| Immunohistochemistry
3 | RESULTS
| Case characteristics
HS tumour samples were obtained from 53 dogs. Sex, age and organ involvement by the neoplastic process are summarized for each dog in Table 1 . No mutation was identified in the 12 control dogs with no neoplastic disease, including 6 BMDs. Moreover, the mutation was not detected in the paired normal tissues from 10 BMDs ( Figure 1A ,B).
In 11 BMDs with PTPN11 E76K mutation, the prevalence of PTPN11 E76K mutation in disseminated HS of BMDs is 6 of 21 (29%), while the prevalence in localized HS in BMDs is 5 of 9 (56%). In regard to other breeds, the PTPN11 E76K mutation was detected in only 1 of 7 disseminated HS (14%) and 1 of 16 localized HS (6%).
| Activation of downstream signalling of PTPN11 E76K detected by IHC
We examined the activation of potential downstream targets of PTN11 in 6 HS cases. In humans, the gain-of-function mutation 
| DISCUSSION
In this study, we identified a somatic mutation in the PTPN11 gene in HS in dogs. This mutation was located in exon 3, leading to the substitution of glutamic acid (E; a negatively charged residue), by lysine (K; a positively charged residue) at position 76 in the N-terminal SH2
domain of the SHP2 gene encoded by PTPN11. This mutation is the most common and most active PTPN11 mutation found in human acute leukaemias. 33 The most striking observation is the significantly 19 and Rapamycin, a potent and selective inhibitor of mTOR, may be effective for the treatment of PTPN11 mutation-mediated neoplasms. While multiple catalytic SHP2 inhibitors have been described, they have shown low potency and specificity. 40, 41 Very recently, SHP099 has been shown to be the first potent, selective and orally bioavailable allosteric PTP inhibitor specific to SHP2 that is efficacious and well-tolerated in patient-derived tumour xenograft models. 24 It is possible that an SHP inhibitor may be successful for the treatment of HS in BMD due to its high frequency of PTPN11 E76K .
While we are able to show a high prevalence of the PTPN11 E76K somatic mutation in HS in BMDs, that is highly suggestive of an association of this mutation with aggressive behaviour, the prognostic significance of this mutation could not be definitely determined as no survival data were available for these cases. Additional studies, investigating the association the PTPN11 E76K mutation with clinical outcome and the prevalence of this mutation in other forms of HS, including periarticular HS, are needed to further elucidate this question.
In conclusion, this study is the first report of the PTPN11 E76K somatic mutation, and the first potential driver mutation in canine HS. Our IHC suggests a gain-of-function nature of this mutation mediated by activation of the downstream ERK1/2 and AKT signalling pathways; however, these results need to be confirmed in a larger cohort. The high prevalence of this mutation in BMDs compared with other dog breeds warrants further study into the relationship between this mutation and the highly aggressive form of HS in BMDs. In addition, novel treatment avenues targeting SHP2 activity as well as its downstream cascades are worth exploring for therapeutic approaches for the treatment of HS.
